Articles tagged with Hemodialysis
A study found that a structured quality improvement program called RightStart improved outcomes for new dialysis patients, including significant reductions in mortality and hospitalization rates. The program, which included education, close medical follow-up, and self-empowerment, was associated with better nutrition, less anemia, and ...
Researchers at Massachusetts General Hospital found a strong association between exposure to gadolinium-containing contrast agents and the development of nephrogenic systemic fibrosis (NSF) in kidney failure patients. The study also showed that individuals with NSF had a significantly increased risk of dying within two years.
Research suggests that frequent nocturnal hemodialysis can reduce the need for blood pressure medications and improve quality of life measures. However, it did not show benefits in anemia management. The study found reduced left ventricular hypertrophy and improved mineral metabolism.
Recent progress in preventing and treating end-stage renal disease (ESRD) in the US is cause for cautious optimism, with improvements in survival expectations and increased use of fistulas for hemodialysis. However, skyrocketing costs are a major concern, with Medicare costs reaching $20.1 billion in 2004.
The American Society of Nephrology reviews disaster response plans to ensure dialysis services are protected for patients with end-stage renal failure. The Kidney Community Emergency Response Coalition outlines recommendations for establishing a timeline to safety and creating individualized disaster plans.
As dialysis care becomes more cost-controlled, nephrologists play a crucial role in maintaining the unique relationship between patients and kidney specialists. The ASN urges a renewed focus on this relationship to ensure high-quality patient care.
A study found that large, for-profit dialysis facilities administer higher doses of epoetin to treat anemia in patients with kidney disease compared to nonprofit facilities. Facility ownership and chain status have a strong impact on epoetin dosing practice patterns.
Researchers at Johns Hopkins found that statins significantly reduce the risk of sepsis in patients undergoing kidney dialysis. The study, published in JAMA, followed 1041 patients for 10 years and found a 41-case risk in the statin group compared to 110 cases in the non-statin group.
A new, nanoporous ceramic filter developed by Lehigh University engineers could make dialysis sessions more efficient and shorter. The filter promises to double the amount of toxins removed during dialysis and increase glomular filtration rate (GFR), leading to improved mortality rates and quality of life for patients.
Researchers create a super-thin membrane, 50 atoms thick, that can sort individual molecules with high efficiency. This innovation has the potential to revolutionize dialysis, fuel cells, and neuro-stem cell cultivation.
The number of very elderly beginning dialysis increased from 1996 to 2003, with one-year survival rates remaining at around 50%. Ambulatory techniques for diagnosing sleep apnea were found to be as effective as polysomnography.
A research team has identified a protective gene variant that may help prevent severe kidney failure in people with diabetes. The discovery could lead to novel treatment approaches for susceptible individuals, as well as a new marker for identifying those at increased risk of future kidney disease.
A recent study reveals that medical misdiagnoses often result from multiple breakdowns in the diagnostic process, including failure to order tests or follow up on patients. In contrast, patients receiving high-quality hemodialysis care are less likely to experience hospitalizations and deaths.
A combined liver and kidney transplant has been shown to improve patient survival rates for those with dual organ disease, including hepatorenal syndrome. The study found that patients who underwent dialysis for longer than two months prior to surgery fared better after the combined transplant.
A study led by Rutgers College of Nursing faculty members will investigate the association between the nursing work environment and nurse-reported patient outcomes. The survey aims to gather data from 2,000 registered nurses practicing in dialysis centers across the US, focusing on adverse events and burnout.
A five-month study published in the American Journal of Physical Medicine and Rehabilitation found that exercise during dialysis increases urea removal by 20% and improves physical function. Participants exercised three times a week, resulting in enhanced dialysis efficacy and better quality of life.
A large-scale phase IV trial found FOSRENOL significantly reduced daily tablet burden and improved patient satisfaction, while maintaining mean serum phosphorus control. Higher initial doses of FOSRENOL more rapidly controlled hyperphosphatemia without increasing adverse events.
The shift in commonly used PTH assay has led to inconsistent results, potentially causing increased parathyroidectomy rates, unnecessary medication use, and adynamic bone disease among dialysis patients. Researchers have developed a more specific assay for PTH to address these concerns.
Researchers found that 22.8% of dialysis patients had other close family members with end-stage kidney disease on dialysis. The study suggests that primary care physicians should consider screening high-risk family members to slow the progression of kidney failure.
Night-time hemodialysis patients showed comparable cardiovascular measures to healthy patients, with restored endothelial progenitor cell biology and improved blood pressure. This therapy may address high cardiovascular morbidity and mortality in end-stage renal disease patients.
A novel artificial kidney utilizing nanotechnology may eliminate dialysis needs for millions worldwide. The HNF system features a wearable design with double the filtration rate of conventional hemodialysis.
A study examining global prevalence of kidney failure among critically ill patients found that septic shock was the most common contributing factor (47.5%). The overall hospital death rate was 60.3%, with dialysis dependence at discharge being 13.8% for survivors.
A recent study by Mayo Clinic researchers found that patients with high levels of heparin antibodies during hemodialysis have higher rates of adverse outcomes. The study suggests that detecting these antibodies may help identify patients at risk for complications, leading to potential improvements in treatment.
A new analysis of existing studies reveals that individuals with overweight or obesity are at a higher risk of experiencing GERD symptoms, erosive esophagitis, and esophageal cancer. In contrast, researchers found no significant difference in mortality rates between patients undergoing peritoneal dialysis or hemodialysis for end-stage ...
The study found that hemodialysis was more beneficial for patients with cardiovascular disease, while peritoneal dialysis was better suited for healthier patients. The findings suggest that choosing the right dialysis treatment can impact mortality rates.
A recent study at Mayo Clinic found that transplanting kidneys with small stones does not significantly affect the kidney's function. The study followed 44 donor kidneys, of which 86% had stones smaller than 2mm, and reported a 97% graft survival rate after 26 months, comparable to national averages for living kidney donation.
Researchers identify TRPC6 gene as novel mechanism for FSGS, a leading cause of kidney damage. The discovery raises hope for new treatments targeting ion channels, which are amenable to drug therapy.
Chronic inflammation during dialysis enhances oxidative stress, leading to cardiovascular disease, malnutrition, and poor outcomes. Antioxidant supplementation and ROS modulation are proposed solutions to prevent these complications.
A University of Maryland study found that more than 86% of dialysis patients with severe heart failure experienced improved cardiac function after a kidney transplant. The study, which followed 103 patients between 1998 and 2002, suggests that a timely transplant can significantly improve heart health for these patients.
The government is funding an ineffective drug cure for chronic hemodialysis patients, with costs estimated at $8086 per year per person. Dr. Theodore Steinman argues that more and better studies are needed before L-carnitine can be used on a wide scale basis.
A recent study found that vitamin D injections can reduce mortality rates by up to 20% in dialysis patients. Currently, only half of kidney failure patients receive this treatment, highlighting the need for more aggressive treatment strategies.
A retrospective study of over 500 patients found that obese kidney donors experienced similar short-term outcomes to non-obese donors, despite prior cardiovascular disease risks. The study highlights the need for longer follow-up periods to assess potential long-term differences in obese donors.
A study of 6,658 children found obese patients had a five-year mortality rate double that of non-obese peers. Obese children often receive transplants at younger ages and experience more cardiovascular complications.
Researchers at MCG Medical Center are studying a bioartificial kidney that can mimic the functions of natural kidneys, reducing mortality rates in ICU patients. The device, developed by Dr. H. David Humes, uses billions of donor kidney cells to filter waste and regulate various bodily processes.
Studies found that sit-down rounds significantly improved patient outcomes, including healthy levels of albumin and hemoglobin, lower hospitalization rates, and reduced mortality. Patients treated at clinics with regular sit-down rounds had better care team communication and were more likely to be white, married, or high school graduates.
A recent study published in Hepatology found that occult HBV infection is prevalent in adult hemodialysis patients, with a rate four to five times higher than standard HBsAg testing. The majority of infections were associated with low viral loads and the sG145R-mutant.
A new global approach aims to combat the growing threat of kidney disease by promoting early detection and proper care. This strategy has been shown to be effective in treating kidney disease, particularly when combined with evidence-based guidelines and actual clinical practice.
A collaboration between pharmaceutical manufacturers, healthcare agencies, and researchers led to a significant reduction in epoetin-associated pure red-cell aplasia. The incidence decreased by 83% after improvements were made in storage and handling of the drug.
Researchers found hospitalizations drive cost increase before dialysis, emphasizing the importance of optimal chronic kidney disease management. Early diagnosis and intervention may prevent avoidable morbidity and reduce future healthcare expenses.
Research challenges previous findings on higher hematocrits achieved through epoetin treatment for end-stage renal disease patients. Cotter's analysis suggests that the current spending on Epogen dosages may not be justified, considering the lack of evidence supporting its survival benefits.
Researchers found that patients with kidney transplants from donors aged 55-79 had comparable allograft survival rates as those from younger donors. The study also revealed that older recipient patients may benefit from receiving kidneys from older deceased or living donors, particularly those facing prolonged waiting times on dialysis.
FOSRENOL, a lanthanum carbonate-based treatment, has been approved for reducing phosphate risk in dialysis patients with end-stage renal failure. The treatment has shown effectiveness and well-tolerability in studies, improving bone disease outcomes.
A new study will compare patients who receive dialysis six times a week to those on the standard three-times-a-week plan. The researchers aim to determine if more frequent dialysis can prevent urea buildup, improve blood pressure, and enhance quality of life.
A $3.3 million NIH grant-funded study will compare six-times-per-week overnight home hemodialysis to standard three-times-a-week hemodialysis at dialysis centers. The research aims to determine if the higher dose of dialysis improves patient outcomes, including hospitalization rates and quality of life.
A study found that both hemodialysis and peritoneal dialysis improved general functioning and well-being, but with different outcomes. Peritoneal dialysis patients showed improvements in finances, while hemodialysis patients had better sleep.
A study by Johns Hopkins researchers found that patients on peritoneal dialysis rate their care as excellent, citing independence, access to staff, and quality of treatment. In contrast, hemodialysis patients report lower satisfaction rates, with many citing inadequate information and economic factors as barriers.
A study published in JAMA found that patients on peritoneal dialysis were more likely to give high ratings of care compared to those on hemodialysis. The researchers also found better survival rates for peritoneal dialysis patients, especially in the first two years after starting treatment.
Dialysis patients with inflammation or malnutrition have lower cholesterol levels than those without. Higher cholesterol is associated with lower mortality among patients without these conditions, but not among those with them.
A 11-week study showed lanthanum carbonate significantly reduced serum phosphorus levels in hemodialysis patients, meeting the new K/DOQI guidelines. Sixty percent of patients achieved target levels, with lower calcium x phosphate product.
Researchers found that while black and white Americans have the same amount of early kidney disease, black patients are five times more likely to progress to end-stage renal disease. This disparity may be due to differences in blood pressure control, quality of care, and access to healthcare.
A new study published in the New England Journal of Medicine found that paricalcitol, a newer vitamin D formulation, has a significant impact on improving survival rates among dialysis patients. The study showed a 16% better survival rate for patients taking paricalcitol compared to those taking calcitriol.
A study of 224 patients with end-stage renal disease found that blood tests measuring troponin T and C-reactive protein can detect silent, small heart attacks and coronary artery disease. The results may help doctors gauge the risk of heart disease in dialysis patients without cardiac symptoms.
Phosphate reduction is achieved within a week of treatment with lanthanum carbonate, a new phosphate binder. This effective treatment reduces serum calcium levels and improves cardiovascular health in end-stage renal disease (ESRD) patients.
A new study reveals that bone morphogenic protein-7 (BMP-7) can reverse chronic kidney injury by reducing scar tissue and repairing damaged areas. This breakthrough could lead to a cost-effective treatment alternative for patients currently undergoing dialysis, significantly improving their quality of life.
Long-term data show effective control of serum phosphate levels, with 71.7% achieving target levels after one year and 68.9% after three years. Low incidence of hypercalcaemia is also maintained throughout the study period.
A study published in the Journal of Infectious Diseases found that people undergoing hemodialysis are 257 times more likely to contract Staphylococcus aureus (ISA) than the general population. Those with HIV, solid organ transplant recipients, and heart disease patients are also at increased risk.
A man with kidney disease experienced severe abdominal pain after using a whirlpool in a Jacuzzi, highlighting potential health risks. The case study suggests that whirlpooling may cause mechanical injury to the kidneys, particularly under conditions like hypertension or anticoagulation.
A recent study published in The New England Journal of Medicine found that higher doses of hemodialysis and more permeable artificial kidneys did not improve survival rates for all patients with end-stage kidney disease. However, selected subgroups, such as women and those treated with a more permeable membrane, showed significant impr...
A study published in JAMA found that ICU patients treated with diuretics have a 68% increase in mortality and 77% non-recovery of kidney function. The researchers suggest reassessing diuretic use, particularly for those not responding to treatment, as delays can lead to adverse outcomes.
UF researchers found that patients who wait longer for a kidney transplant are more likely to experience poorer outcomes. The study showed that even those who receive kidneys from living donors may not reap the full benefits if they have been on dialysis for too long.